AR084868A2 - Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos - Google Patents
Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlosInfo
- Publication number
- AR084868A2 AR084868A2 ARP120100145A ARP120100145A AR084868A2 AR 084868 A2 AR084868 A2 AR 084868A2 AR P120100145 A ARP120100145 A AR P120100145A AR P120100145 A ARP120100145 A AR P120100145A AR 084868 A2 AR084868 A2 AR 084868A2
- Authority
- AR
- Argentina
- Prior art keywords
- testosterone
- pharmaceutical formulation
- antineoplastic agent
- vintinine
- temozolomide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulación farmacéutica que comprende al menos un agente antineoplásico o una sal farmacéuticamente aceptable del mismo, y al menos un agente mejorador de la disolución suficiente para disolver sustancialmente el agente antineoplásico en al menos un diluyente acuoso, donde el agente mejorador de la disolución es urea, L-histidina, L-treonina, L-asparragina, L-serina, L-glutamina o mezclas de las mismas; un polvo liofilizado que comprende la formulación farmacéutica, y artículos de manufactura de los mismos.Reivindicación 2: La formulación farmacéutica de acuerdo con la reivindicación 1, donde el agente antineoplásico es temozolomida, uracilo mostaza, clormetina, ciclofosfamida, ifosfamida, melfalan, clorambucil, pipobroman, trietilenmelamina, trietilentiofosforamida, busulfan, carmustina, lomustina, estreptozocina, dacarbazina, metotrexato, 5-fluoruracilo, floxuridina, citarabina, 6-mercaptopurina, 6-tioguanina, fosfato de fludarabina, pentostatina, gemcitabina, vinblastina, vincristina, vindesina, bleomicina, dactinomicina, daunorubicina, doxorubicina, epirubicina, idarubicina, paclitaxel, mitramicina, deoxicoformicina, mitomicina-C, L-asparraginasa, interferones, etoposida, teniposida, 17.a-etinilestradiol, dietilestilbestrol, testosterona, prednisona, fluoximesterona, propionato de dromostanolona, testolactona, megestrolacetato, tamoxifen, metilprednisolona, metiltestosterona, prednisolona, triamcinolona, clorotrianiseno, hidroxiprogesterona, aminoglutetimida, estramustina, medroxiprogesteronacetato, leuprolida, flutamida, toremifeno, goserelina, cisplatina, carboplatina, hidroxiurea, amsacrina, procarbazina, mitotano, mitoxantrona, levamisol, navelbeno, anastrazol, letrazol, capecitabina, reloxafina, droloxafina, hexametilmelamina, y mezclas de los mismos. Reivindicación 3: La formulación farmacéutica de acuerdo con la reivindicación 2, donde el agente antineoplásico es temozolomida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35919802P | 2002-02-22 | 2002-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084868A2 true AR084868A2 (es) | 2013-07-10 |
Family
ID=27766051
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100551A AR038535A1 (es) | 2002-02-22 | 2003-02-20 | Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos |
ARP080100003A AR064722A2 (es) | 2002-02-22 | 2008-01-02 | Procesos para preparar formulaciones farmaceuticas de agentes antineoplasicos, polvo liofilizado, articulo que lo comprende y formulacion farmaceutica |
ARP120100145A AR084868A2 (es) | 2002-02-22 | 2012-01-16 | Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100551A AR038535A1 (es) | 2002-02-22 | 2003-02-20 | Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos |
ARP080100003A AR064722A2 (es) | 2002-02-22 | 2008-01-02 | Procesos para preparar formulaciones farmaceuticas de agentes antineoplasicos, polvo liofilizado, articulo que lo comprende y formulacion farmaceutica |
Country Status (24)
Country | Link |
---|---|
US (9) | US6987108B2 (es) |
EP (1) | EP1478339B9 (es) |
JP (2) | JP4077794B2 (es) |
KR (1) | KR100970528B1 (es) |
CN (2) | CN101172104B (es) |
AR (3) | AR038535A1 (es) |
AT (1) | ATE397440T1 (es) |
AU (1) | AU2003213142B2 (es) |
BR (1) | BRPI0307802B8 (es) |
CA (2) | CA2476494C (es) |
CY (1) | CY1108291T1 (es) |
DE (1) | DE60321450D1 (es) |
DK (1) | DK1478339T3 (es) |
ES (1) | ES2307905T3 (es) |
HK (1) | HK1066466A1 (es) |
MX (1) | MXPA04008133A (es) |
NO (1) | NO335045B1 (es) |
NZ (1) | NZ534378A (es) |
PL (1) | PL205936B1 (es) |
PT (1) | PT1478339E (es) |
SG (1) | SG161101A1 (es) |
SI (1) | SI1478339T1 (es) |
WO (1) | WO2003072082A1 (es) |
ZA (1) | ZA200406632B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2476494C (en) * | 2002-02-22 | 2010-04-27 | Schering Corporation | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same |
US8188067B2 (en) | 2004-04-01 | 2012-05-29 | Teva Pharmaceutical Industries Ltd. | Formulations of 6-mercaptopurine |
US20060008520A1 (en) * | 2004-04-01 | 2006-01-12 | Lerner E I | Delayed release formulations of 6-mercaptopurine |
US20060122162A1 (en) * | 2004-12-02 | 2006-06-08 | Schering Corporation | Methods of using temozolomide formulation intrathecally in the treatment of cancers |
MX2008014953A (es) * | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US20100119592A1 (en) * | 2006-12-08 | 2010-05-13 | Bruce Michael Frankel | Cytarabine for treatment of glioma |
FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
EP2409700A1 (en) * | 2007-05-08 | 2012-01-25 | Schering Corporation | Methods of treatment using intravenous formulations comprising temozolomide |
US20080319039A1 (en) * | 2007-06-25 | 2008-12-25 | Jacqueline Rose Bersch | Unit dosage forms of temozolomide |
CN101467967B (zh) * | 2007-12-29 | 2012-05-23 | 北京京卫燕康药物研究所有限公司 | 用于静脉和脑内注射的两元溶液型制剂 |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
CN101559037B (zh) * | 2008-04-16 | 2013-01-30 | 北京京卫燕康药物研究所有限公司 | 用于静脉和脑内注射的两元溶液型制剂 |
EP2110130A1 (en) * | 2008-04-18 | 2009-10-21 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical use of 6-mercaptopurine |
PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
AR066943A1 (es) * | 2008-06-10 | 2009-09-23 | Eriochem Sa | Una composicion farmaceutica de melfalano |
EP2313093A4 (en) | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY |
MX2022000192A (es) | 2008-09-30 | 2022-03-02 | Shaw Ind Group Inc | Composiciones de tereftalato de polietileno reciclado, fibras y articulos producidos a partir de las mismas, y metodos para producirlas. |
MX2022000197A (es) | 2008-09-30 | 2022-03-02 | Shaw Ind Group Inc | Composiciones de tereftalato de polietileno reciclado, fibras y articulos producidos a partir de las mismas, y metodos para producirlas. |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
EP2396000A1 (en) * | 2009-02-11 | 2011-12-21 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
WO2011036676A2 (en) | 2009-09-23 | 2011-03-31 | Ashwini Nangia | Stable cocrystals of temozolomide |
CN103180339B (zh) | 2010-05-26 | 2016-04-27 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
CN101869551B (zh) * | 2010-06-28 | 2012-04-18 | 江苏奥赛康药业股份有限公司 | 一种替莫唑胺冻干制剂 |
CN102342931B (zh) * | 2010-07-29 | 2014-04-23 | 江苏恒瑞医药股份有限公司 | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 |
CN101984968A (zh) * | 2010-10-29 | 2011-03-16 | 北京润德康医药技术有限公司 | 抗肿瘤剂替莫唑胺的药物制剂制备方法 |
CN102659789B (zh) * | 2011-04-27 | 2014-10-15 | 四川科瑞德凯华制药有限公司 | 一锅法制备替莫唑胺的方法及替莫唑胺的精制方法 |
PL2701720T3 (pl) | 2011-04-28 | 2017-12-29 | Oncopeptides Ab | Liofilizowany preparat cytotoksycznych dipeptydów |
CN102178676B (zh) * | 2011-04-29 | 2012-07-25 | 山东大学 | 一种治疗脑胶质瘤的药物组合物 |
CN102949351B (zh) * | 2011-08-16 | 2015-05-13 | 上海汇伦生命科技有限公司 | 一种替莫唑胺冻干制剂的制备方法 |
CN102688202B (zh) * | 2012-06-07 | 2013-08-14 | 北京莱瑞森医药科技有限公司 | 一种替莫唑胺冻干制剂 |
US8974811B2 (en) * | 2013-03-14 | 2015-03-10 | Hikma Pharmaceuticals | Stabilized pharmaceutical formulations comprising antineoplastic compounds |
CN104274412A (zh) * | 2013-07-01 | 2015-01-14 | 北京恒瑞康达医药科技发展有限公司 | 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂 |
CN103432085A (zh) * | 2013-08-19 | 2013-12-11 | 南京海纳医药科技有限公司 | 一种含氨基酸增溶剂的替莫唑胺冻干制剂及其制备方法 |
EP2865391B1 (de) | 2013-10-22 | 2017-09-20 | medac Gesellschaft für klinische Spezialpräparate mbH | Verfahren zur Herstellung einer gefriergetrockneten pharmazeutischen Zusammensetzung mit Gehalt an Mitomycin C |
US10583210B2 (en) * | 2014-06-20 | 2020-03-10 | Syddansk Universitet | Auger electron therapy for glioblastoma |
EA201790378A1 (ru) * | 2014-08-14 | 2017-07-31 | Л.Е.А.Ф. ХОЛДИНГЗ ГРУП ЭлЭлСи | Заключенное в липосому аффинное лекарственное средство |
BR112017014996A2 (pt) | 2015-01-14 | 2018-03-20 | Chiesi Farm Spa | formulações farmacêuticas e recipientes selados |
EP3362053A4 (en) | 2015-10-16 | 2019-04-17 | Hadasit Medical Research Services and Development Ltd. | TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE |
WO2017192088A1 (en) * | 2016-05-02 | 2017-11-09 | Double Bond Pharmaceuticals Ab | Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition |
JP6706988B2 (ja) * | 2016-07-20 | 2020-06-10 | 日本化薬株式会社 | ボルテゾミブを含有する医薬組成物 |
JOP20190204A1 (ar) * | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
CN107213123A (zh) * | 2017-07-23 | 2017-09-29 | 南京正宽医药科技有限公司 | 一种注射用盐酸氨溴索及其制备方法 |
BE1025934B1 (fr) * | 2018-01-12 | 2020-05-05 | Hyloris Dev Sa | Suspension pharmaceutique de méthylprednisolone |
MX2021012250A (es) | 2019-04-11 | 2022-01-18 | Angion Biomedica Corp | Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol. |
WO2021108601A1 (en) * | 2019-11-25 | 2021-06-03 | The Johns Hopkins University | Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors |
WO2021229442A1 (en) | 2020-05-12 | 2021-11-18 | Shorla Pharma Ltd | Stable formulations of temozolomide for oral administration |
WO2024071464A1 (ko) * | 2022-09-27 | 2024-04-04 | (주)바이오솔릭스 | 말레이트 금속염을 포함하는 항암용 조성물 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4455256A (en) * | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
US5260291A (en) * | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US5731304A (en) * | 1982-08-23 | 1998-03-24 | Cancer Research Campaign Technology | Potentiation of temozolomide in human tumour cells |
JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
US5204335A (en) | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
JPS63313721A (ja) * | 1987-06-17 | 1988-12-21 | Teisan Seiyaku Kk | 速溶性の注射用組成物 |
SU1479049A1 (ru) * | 1987-07-01 | 1989-05-15 | Научно-производственное объединение "Биолар" | Способ получени концентрата водорастворимых фосфолипидов |
US5066647A (en) | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
JP2977236B2 (ja) * | 1990-07-20 | 1999-11-15 | 株式会社東芝 | 音声合成装置 |
US5268368A (en) * | 1991-05-17 | 1993-12-07 | Erbamont, Inc. | Cyclophosphamide--amino acid lyophilizates |
US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
JPH08505615A (ja) * | 1993-01-14 | 1996-06-18 | キャンサー・リサーチ・キャンペーン・テクノロジー・リミテッド | ヒト腫瘍細胞におけるテモゾロミドの薬効の増強 |
DE4331147A1 (de) * | 1993-09-14 | 1995-03-16 | Nycomed Arzneimittel Gmbh | Intravenös verabreichbare, wäßrige Lösung |
FR2740686B1 (fr) | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
TWI243057B (en) | 1998-03-26 | 2005-11-11 | Schering Corp | Formulations for protection of peg-interferon alpha conjugates |
US6251886B1 (en) * | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
US5972912A (en) | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
CN1434825A (zh) * | 1999-12-24 | 2003-08-06 | 拜尔公司 | 咪唑并[1,3,5]三嗪酮及其应用 |
CA2476494C (en) | 2002-02-22 | 2010-04-27 | Schering Corporation | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same |
US20060100188A1 (en) | 2004-11-09 | 2006-05-11 | Chen Zong | Treatment methods |
-
2003
- 2003-02-20 CA CA2476494A patent/CA2476494C/en not_active Expired - Lifetime
- 2003-02-20 NZ NZ534378A patent/NZ534378A/en not_active IP Right Cessation
- 2003-02-20 AU AU2003213142A patent/AU2003213142B2/en active Active
- 2003-02-20 KR KR1020047012686A patent/KR100970528B1/ko active Protection Beyond IP Right Term
- 2003-02-20 SI SI200331262T patent/SI1478339T1/sl unknown
- 2003-02-20 ES ES03709188T patent/ES2307905T3/es not_active Expired - Lifetime
- 2003-02-20 JP JP2003570828A patent/JP4077794B2/ja not_active Expired - Lifetime
- 2003-02-20 CA CA002662899A patent/CA2662899A1/en not_active Abandoned
- 2003-02-20 BR BRPI0307802A patent/BRPI0307802B8/pt not_active IP Right Cessation
- 2003-02-20 AT AT03709188T patent/ATE397440T1/de active
- 2003-02-20 CN CN2007101489617A patent/CN101172104B/zh not_active Expired - Lifetime
- 2003-02-20 PT PT03709188T patent/PT1478339E/pt unknown
- 2003-02-20 SG SG200605719-4A patent/SG161101A1/en unknown
- 2003-02-20 MX MXPA04008133A patent/MXPA04008133A/es active IP Right Grant
- 2003-02-20 AR ARP030100551A patent/AR038535A1/es not_active Application Discontinuation
- 2003-02-20 PL PL372319A patent/PL205936B1/pl unknown
- 2003-02-20 CN CNB038043637A patent/CN100346784C/zh not_active Expired - Lifetime
- 2003-02-20 DE DE60321450T patent/DE60321450D1/de not_active Expired - Lifetime
- 2003-02-20 EP EP03709188A patent/EP1478339B9/en not_active Expired - Lifetime
- 2003-02-20 DK DK03709188T patent/DK1478339T3/da active
- 2003-02-20 WO PCT/US2003/005018 patent/WO2003072082A1/en active Application Filing
- 2003-02-21 US US10/371,808 patent/US6987108B2/en not_active Expired - Lifetime
-
2004
- 2004-08-19 ZA ZA2004/06632A patent/ZA200406632B/en unknown
- 2004-09-21 NO NO20043961A patent/NO335045B1/no not_active IP Right Cessation
- 2004-11-26 HK HK04109335A patent/HK1066466A1/xx not_active IP Right Cessation
-
2006
- 2006-01-13 US US11/332,721 patent/US7674790B2/en active Active
-
2007
- 2007-10-22 JP JP2007274513A patent/JP4785816B2/ja not_active Expired - Lifetime
-
2008
- 2008-01-02 AR ARP080100003A patent/AR064722A2/es unknown
- 2008-08-25 CY CY20081100907T patent/CY1108291T1/el unknown
-
2009
- 2009-03-12 US US12/403,113 patent/US7786118B2/en not_active Expired - Lifetime
-
2010
- 2010-07-21 US US12/840,505 patent/US8076335B2/en not_active Expired - Fee Related
-
2011
- 2011-11-07 US US13/290,251 patent/US8623868B2/en not_active Expired - Lifetime
-
2012
- 2012-01-16 AR ARP120100145A patent/AR084868A2/es not_active Application Discontinuation
-
2013
- 2013-12-02 US US14/093,712 patent/US20140088166A1/en not_active Abandoned
-
2015
- 2015-12-03 US US14/957,653 patent/US20160082005A1/en not_active Abandoned
-
2017
- 2017-11-29 US US15/825,296 patent/US20180078546A1/en not_active Abandoned
-
2019
- 2019-07-16 US US16/513,384 patent/US20190336495A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084868A2 (es) | Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos | |
CO5550459A2 (es) | Inhibidor potente de la serina proteasa del vhc | |
AR043863A1 (es) | Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
CA2499756A1 (en) | Imidazopyrazines as cyclin dependent kinase inhibitors | |
HRP20110245T1 (hr) | Derivati pirazolopirimidina kao inhibitori o ciklinu ovisne kinaze | |
AR032524A1 (es) | Composicion farmaceutica para capsulas moldeadas; composicion farmaceutica para envueltas de capsulas moldeadas; envuelta, elemento de union o separador de capsula moldeados por inyeccion con las mismas; forma de dosificacion farmaceutica de varios componentes y conjunto de formas de dosificacion de | |
ECSP066535A (es) | Composiciones y formas de dosis para absorcion mejorada de gabapentina y pregabalina | |
CO5280073A1 (es) | Composiciones | |
AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
CA2497544A1 (en) | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors | |
ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
ECSP066315A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
CA2665543A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
CA2665539A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
AR042511A1 (es) | Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico | |
ECSP088379A (es) | Tabletas dispersables que comprenden deferasirox | |
CA2499639A1 (en) | Imidazopyridines as cyclin dependent kinase inhibitors | |
MX9308188A (es) | Glucomanano de konjac facilmente disponible, como un excipiente de liberacion sostenida. | |
DOP2002000389A (es) | Metodo para fabricar una composición farmaceutica de dosis baja que tiene una distribución y potencia del fármaco uniforme | |
AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
AR029456A1 (es) | Forma triturada | |
BR0212807A (pt) | Processo para a preparação de formas de dosagem de dissolução rápida | |
CA2315693A1 (en) | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases | |
ECSP034915A (es) | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |